Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Open Access
- 17 December 2009
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 148 (2), 256-267
- https://doi.org/10.1111/j.1365-2141.2009.07954.x
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2009
- Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25Blood, 2009
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialBritish Journal of Cancer, 2007
- Sickle Cell Anemia: Targeting the Role of Fetal Hemoglobin in TherapyClinical Pediatrics, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Targeting histone deacetylase in cancer therapyMedicinal Research Reviews, 2006
- Various Methods of Analysis of mdr-1/P-Glycoprotein in Human Colon Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1992